Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2005

View Archived Issues

Peregrine signs licensing agreement with Medarex for vascular targeting agents

New preclinical data support use of OXI-4503 in cancer

Inyx to acquire Celltech Manufacturing Services from UCB

EncorePharma receives phase I SBIR grant for Huntington's disease research

Acambis on track to begin phase III trials of ChimeriVax-JE by year-end

AL-208 enters phase I trials for MCI associated with CABG

Sunesis selects Aurora kinase candidate for preclinical development

New study evaluates Cotara for glioblastoma multiforme

Advaxis completes preclinical toxicology studies for Lovaxin C

SCOLR Pharma completes pilot bioavailability testing of CDT-raloxifene

Enrollment completed in phase II study of ozarelix for prostate cancer

Discovery receives FDA notification regarding Surfaxin response letter

Positive findings in open-label study of Prestara

Preclinical profile of AMG-8163 for the treatment of pain

Preclinical summary on ONO-2921, a Cav2.2 blocker for pain

Actoplus Met approved for type 2 diabetes

sBLA filed for Erbitux for head and neck cancer

New data on Remune presented

CHIR-258 active against acute myelogenous leukemia cells in vitro and in vivo

Novel BK-1 antagonist with high selectivity and good PK profile

TAK-242 subject of presentation at ACS meeting

Maraviroc reported safe and effective in HIV infection

EGIS-11229: A novel noncompetitive AMPA receptor antagonist

Case report: Reboxetine induces weight loss

Recent patents describe novel antiinfective agents

New potential treatments for obesity emerge from pharmaceutical R&D

Novel agents for thrombotic disorders imparted by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...